In recent years, lung cancer screening programs across the United States have brought to light approximately 1.6 million suspicious lung nodules annually. This surge in detection presents a formidable challenge to pulmonologists and oncologists alike. While the overwhelming majority of peripheral pulmonary lesions identified through screening are benign, it is their malignant counterparts that remain the foremost cause of cancer mortality in both men and women. Addressing this diagnostic conundrum, a groundbreaking five-year multisite study conducted by the Mayo Clinic reveals that shape-sensing robotic-assisted bronchoscopy, augmented by mobile cone-beam computed tomography (CBCT), marks a significant advance in the precise, minimally invasive diagnosis of these lesions.
Encompassing an extensive cohort of 1,904 patients and 2,115 lung lesions across Mayo Clinic campuses in Jacksonville, Florida; Phoenix, Arizona; and Rochester, Minnesota, the study spans from 2019 to 2024. This comprehensive investigation endorses the technology’s remarkable sensitivity of 85% in detecting malignant lung growths and establishes a diagnostic yield accuracy of nearly 77% following rigorous, newly unified national criteria. Notably, complications were infrequent, affecting only 2.8% of procedures, underscoring the safety profile of robotic bronchoscopy.
This diagnostic stride has directly translated to a palpable shift in clinical outcomes at the institution. Since its adoption, the proportion of early-stage lung cancer diagnoses leapt from 46% in 2019 to an impressive 69% by mid-2024. Concurrently, late-stage diagnoses declined from 54% to 31%, accentuating the life-saving potential of early intervention. The lead author, Dr. Sebastian Fernandez-Bussy, a prominent pulmonary specialist and research dean at Mayo Clinic Florida, emphasizes that early detection remains the linchpin of successful lung cancer treatment. “Technologies facilitating earlier and less invasive diagnosis ultimately drive improved patient survival,” he asserts.
The genesis of lung cancer often traces back to discrete pulmonary nodules detected via screening modalities. Given the ambiguity in imaging alone, histopathological evaluation through lung biopsies becomes indispensable. Robotic-assisted bronchoscopy, receiving FDA clearance in 2019, enables clinicians to navigate complex airway pathways with unprecedented precision. The shape-sensing technology stabilizes sampling instruments, allowing comprehensive biopsy of multiple suspicious nodules throughout both lungs. This capability is a leap beyond traditional methods that often sample lesions individually or with lower precision.
Integration of endobronchial ultrasound (EBUS) further empowers clinicians to perform accurate mediastinal staging by biopsying regional lymph nodes, crucial in determining the extent of the disease. When combined with real-time 3D imaging modalities such as cone-beam CT scans, the procedure confirms exact tool positioning within lesions, thereby reducing sampling errors. This synergy of robotics and advanced imaging is transforming lung cancer diagnostics into a single-session, highly reliable intervention.
The authors report that over half of the lesions sampled, 56%, were confirmed malignant. Meanwhile, 21% of lesions were definitively benign, and 23% remained nondiagnostic based on the newly established strict criteria. These criteria, promulgated by leading professional societies including the American Thoracic Society and the American College of Chest Physicians, exclude certain follow-up interpretations that previously inflated diagnostic success statistics, thereby ensuring more precise and clinically relevant measures of effectiveness.
Beyond diagnosis, robotic bronchoscopy platforms are increasingly being paired with novel therapeutic modalities. Notably, pulsed electric field ablation (PEF)—a minimally invasive, non-thermal treatment—has emerged as an innovative option especially for patients ineligible for conventional surgery or radiotherapy. Mayo Clinic clinicians have pioneered protocols integrating diagnosis, staging, and immediate treatment within a single anesthetic session. Dr. Janani Reisenauer, chair of thoracic surgery at Mayo Clinic Rochester, calls this the “single anesthetic lung surgery pathway.” She highlights how this approach minimizes hospital visits, reduces patient downtime, and accelerates recovery, fundamentally shifting paradigms in lung cancer care.
Survival statistics starkly underscore the imperative for early diagnosis, with five-year survival rates approaching 67% for localized lung cancer compared to a dismal 12% once metastatic spread has occurred. Hence, national guidelines now emphasize timely evaluation and intervention after screening detects suspect lesions. With lung cancer screening expected to broaden and more nodules identified, demand for sophisticated, minimally invasive diagnostic modalities is anticipated to rise sharply.
This landmark study, published in Mayo Clinic Proceedings, also showcases the invaluable role of patient-contributed biospecimens paired with detailed clinical data. Mayo Clinic’s Bioresource initiative exemplifies how large biorepositories enable accelerating translational research, fostering discovery, and propelling the development of targeted therapies. As robotic bronchoscopy technologies continue to evolve and integrate with cutting-edge imaging and ablation techniques, patients stand to benefit from significantly improved diagnostic accuracy, streamlined care pathways, and better long-term survival outcomes.
In sum, the advent of shape-sensing robotic-assisted bronchoscopy combined with real-time mobile cone-beam CT signals a transformative chapter in lung cancer diagnosis and management. By enhancing biopsy precision, enabling comprehensive staging, and facilitating immediate therapeutic intervention, this approach addresses a critical clinical need with tailored, patient-centered solutions. As this technology gains wider adoption, it promises to reshape current standards and ultimately reduce the global burden of lung cancer mortality through earlier detection and more effective treatment.
Subject of Research: People
Article Title: 2000 Peripheral Pulmonary Lesions Sampled by Shape-Sensing Robotic-Assisted Bronchoscopy and Mobile Cone-Beam Computed Tomography
News Publication Date: 4-Mar-2026
Web References: http://dx.doi.org/10.1016/j.mayocp.2025.11.015
References: Mayo Clinic Proceedings, DOI: 10.1016/j.mayocp.2025.11.015
Keywords: Lung cancer, robotic bronchoscopy, pulmonary nodules, cone-beam CT, shape-sensing technology, endobronchial ultrasound, lung biopsy, minimally invasive diagnosis, early detection, pulsed electric field ablation, lung cancer staging, thoracic surgery
Tags: advancements in peripheral pulmonary lesion diagnosisdiagnostic accuracy of robotic bronchoscopyimpact of robotic technology on oncology outcomeslung cancer screening programs in the USMayo Clinic multisite bronchoscopy studyminimally invasive lung nodule biopsy techniquesmobile cone-beam computed tomography in pulmonologyreducing complications in lung cancer diagnosticsrobotic bronchoscopy for lung cancer diagnosissafety profile of robotic bronchoscopy proceduressensitivity of lung lesion detection methodsshape-sensing robotic-assisted bronchoscopy
